FDAnews
www.fdanews.com/articles/101623-revlimid-receives-orphan-medicinal-product-designation

Revlimid Receives Orphan Medicinal Product Designation

November 30, 2007

Celgene’s Swiss subsidiary, Celgene International Sarl, has been granted orphan medicinal product designation by the European Commission for Revlimid, a treatment of chronic lymphocytic leukemia.

In the European Union (EU), Iceland and Norway, Revlimid (lenalidomide), in combination with dexamethasone, is indicated for treating multiple myeloma patients who have received at least one therapy. The drug also is approved in the U.S. and Switzerland for this indication, Celgene said.

Revlimid has obtained orphan drug designation in the EU, U.S., Switzerland and Australia for the treatment of multiple myeloma and in the EU, Australia and U.S. for myelodysplastic syndrome.